查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933348

全球乙型肝炎治疗市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的分析以及未来预测（2026-2034）

Hepatitis B Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 161 Pages | 商品交期: 请询问到货日

价格

B型肝炎治疗市场成长因素

受乙型肝炎感染病例增加以及政府加强宣传、提高诊断率和治疗普及率等因素的推动，全球乙型肝炎治疗市场正经历强劲增长。根据 Fortune Business Insights 的一项研究显示，2025 年全球乙型肝炎治疗市场规模预计将达到 24.8 亿美元。预计该市场将从 2026 年的 26.7 亿美元成长到 2034 年的 66.6 亿美元，预测期内复合年增长率 (CAGR) 为 12.09%。北美地区凭藉先进的医疗基础设施和较高的治疗普及率，在 2025 年将以 52.31% 的市场占有率领先。

乙型肝炎的治疗方法包括抗病毒药物和免疫调节剂，用于治疗急性和慢性乙型肝炎病毒 (HBV) 感染。 HBV 的传播途径包括性接触、接触受感染的血液和体液，以及分娩期间的母婴传播。日益加重的全球疾病负担以及对消除病毒性肝炎这一公共卫生威胁的日益重视，是推动市场扩张的关键因素。

市场动态

市场驱动因素

B型肝炎盛行率的上升是推动市场成长的关键因素。乙型肝炎是一种严重的肝臟感染，如果不治疗，可发展为慢性疾病、肝硬化和肝细胞癌。根据世界卫生组织 (WHO) 截至 2022 年对 187 个国家的数据，全球约有 2.54 亿人感染B型肝炎，但只有一小部分慢性患者接受治疗。 大量未接受治疗的患者群体推动了对有效诊断方法和长期治疗管理的需求，从而促进了乙型肝炎治疗市场的成长。

市场限制因子

慢性B型肝炎患者抗病毒药物抗药性的出现是主要限制因素。长期使用核苷/核苷酸类似物会导致病毒突变，降低药物疗效并导致治疗失败。对拉米夫定和阿德福韦酯等常用药物的抗药性限制了其长期疗效，阻碍了持续治疗，并抑制了市场成长。

市场机会

现有单药疗法的限制以及抗药性乙型肝炎病毒株的出现，为开发新型疗法和联合疗法创造了充满希望的机会。多家製药和生技公司正在开发针对乙型肝炎病毒生命週期多个阶段的在研产品。预计在预测期内，联合疗法和新一代抗病毒药物将满足未被满足的医疗需求，并显着扩展治疗选择。

市场挑战

长期抗病毒治疗的高昂费用仍然是一项重大挑战，尤其是在中低收入国家。慢性B型肝炎需要长期治疗和持续监测，对患者和医疗保健系统造成沉重的经济负担。每日口服药物依从性低进一步增加了抗药性的风险，对市场的可持续成长构成挑战。

B型肝炎药物市场趋势

市场的一个显着趋势是，人们越来越关注针对共价闭合环状DNA (cccDNA) 和整合的乙型肝炎病毒DNA的治癒性疗法，这些DNA是导致持续性病毒感染的原因。目前的疗法可以抑制病毒复製，但无法根除cccDNA，导致疾病復发。 这种情况加速了基因编辑、RNA干扰和免疫疗法的研究，预示着慢性B型肝炎的治疗方向正转向根治性治疗。

市场区隔分析

依药物类别划分，核苷类似物将在2026年占市场主导地位，市占率达74.03%。这主要归功于其广泛的处方历史以及抑制病毒复製的能力。核苷酸类似物曾占第二大市场占有率，但由于抗药性的增加，其成长速度已放缓。干扰素将保持相当大的市场占有率，这得益于联合疗法研究的持续开展；而其他细分市场预计将因新型疗法的开发而实现显着增长。

依年龄组别划分，成人将在2026年占最大市场占有率，达77.87%。这主要归功于较高的感染率和扩大的成人筛检项目。由于有效的疫苗接种计划，儿童的市场占有率将相对较小，但随着适应症的扩大，其市场占有率预计将保持适度增长。

依给药途径划分，口服给药途径将在2026年占市场主导地位，市占率高达94.76%，主要得益于其便利性和病患依从性。由于生物利用度的提高和新型注射疗法的出现，肠外给药途径预计将稳定成长。

依分销管道划分，零售药局将在2026年占市场主导地位，市场占有率为52.53%，而线上药局预计将以最高的复合年增长率增长，这主要得益于数位化进程的推进。

区域展望

北美地区将在2025年占市场主导地位，市场规模将达到13.2亿美元，主要得益于较高的疾病认知度和强有力的健保政策。 预计2026年，美国市场规模将达到13.6亿美元。

亚太地区占第二大市场占有率，预计成长速度最快，这主要得益于该地区疾病高发生率和价格低廉的仿製药的广泛普及。预计到2026年，中国市场规模将达到5.6亿美元。

欧洲继续占较大市场占有率，这得益于其先进的医疗保健体系和不断上升的乙肝病毒感染率。

由于政府主导的根除计画的增加，拉丁美洲和中东/非洲地区预计将保持稳定成长。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要国家乙型肝炎流行率（2025 年）
  • 主要产业趋势：新产品发布、併购、业务合作等
  • 主要公司产品线分析
  • B型肝炎治疗进展
  • 主要国家乙型肝炎疫苗接种率概述国家/地区
  • 关税对市场的影响

第五章 全球B型肝炎治疗市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依药物类别划分
    • 核苷类似物
    • 核苷酸类似物
    • 干扰素
    • 其他
  • 市场分析、洞察与预测：依年龄组别划分
    • 成人
    • 儿童
  • 市场分析、洞察与预测：依给药途径划分
    • 口服
    • 肠外给药
  • 市场分析、洞察与预测：依通路划分
    • 医院药房
    • 零售药房
    • 线上药房
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美乙型肝炎治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲乙型肝炎治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 德国
    • 美国王国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 其他欧洲国家

第八章 亚太地区乙型肝炎治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章 拉丁美洲乙型肝炎治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区美国

第十章：中东与非洲B型肝炎治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会 (GCC) 国家
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2025）
  • 公司简介
    • Gilead Sciences, Inc.
    • Bristol-Myers Squibb Company
    • GSK plc
    • Excision BioTherapeutics, Inc.
    • Arbutus Biopharma
    • Assembly Biosciences, Inc.
    • Aligos Therapeutics
    • Barinthus Biotherapeutics
Product Code: FBI113651

Growth Factors of hepatitis B therapeutics Market

The global hepatitis B therapeutics market is witnessing strong growth driven by the rising prevalence of hepatitis B infection worldwide and increasing government initiatives to improve awareness, diagnosis, and treatment adoption. According to Fortune Business Insights, the global hepatitis B therapeutics market was valued at USD 2.48 billion in 2025. The market is projected to grow from USD 2.67 billion in 2026 to USD 6.66 billion by 2034, registering a CAGR of 12.09% during the forecast period. In 2025, North America dominated the market with a share of 52.31%, supported by advanced healthcare infrastructure and high treatment adoption rates.

Hepatitis B therapeutics include antiviral drugs and immune-modulating agents used to manage acute and chronic hepatitis B virus (HBV) infections. HBV is transmitted through sexual contact, exposure to infected blood or bodily fluids, and from mother to child during birth. The growing global disease burden and increasing focus on eliminating viral hepatitis as a public health threat are key factors driving the market's expansion.

Market Dynamics

Market Drivers

The rising prevalence of hepatitis B is a major driver of market growth. Hepatitis B is a serious liver infection that can progress to chronic disease, liver cirrhosis, and hepatocellular carcinoma if left untreated. According to the World Health Organization, based on 2022 data from 187 countries, approximately 254 million people globally were living with hepatitis B infection, while only a small proportion of chronic patients were receiving treatment. This large untreated population has increased the demand for effective diagnosis and long-term therapeutic management, thereby driving the hepatitis B therapeutics market.

Market Restraints

The emergence of antiviral drug resistance in chronic hepatitis B patients is a significant restraint. Long-term use of nucleoside and nucleotide analogues can lead to viral mutations, resulting in reduced drug efficacy and treatment failure. Resistance to commonly used drugs such as lamivudine and adefovir dipivoxil has limited their long-term effectiveness, discouraging sustained therapy and restraining market growth.

Market Opportunities

The limitations of existing monotherapies and the growing burden of drug-resistant HBV strains are creating lucrative opportunities for the development of novel and combination therapies. Several pharmaceutical and biotechnology companies are advancing pipeline products targeting multiple stages of the HBV lifecycle. Combination regimens and next-generation antivirals are expected to address unmet clinical needs and significantly expand treatment options during the forecast period.

Market Challenges

High treatment costs associated with long-term antiviral therapy remain a major challenge, particularly in low- and middle-income countries. Chronic hepatitis B requires prolonged treatment and continuous monitoring, increasing financial strain on patients and healthcare systems. Poor medication adherence due to daily oral regimens further elevates the risk of resistance development, posing challenges to sustained market growth.

Hepatitis B Therapeutics Market Trends

A prominent trend in the market is the growing focus on curative therapies targeting covalently closed circular DNA (cccDNA) and integrated HBV DNA, which are responsible for viral persistence. Current therapies suppress viral replication but do not eradicate cccDNA, leading to disease recurrence. This has accelerated research into gene-editing, RNA interference, and immune-based therapies, signaling a shift toward potentially curative treatment approaches for chronic hepatitis B.

Segmentation Analysis

By drug class, nucleoside analogues dominated the market with a share of 74.03% in 2026, driven by their widespread prescription and effectiveness in suppressing viral replication. Nucleotide analogues held the second-largest share but showed slower growth due to rising resistance. Interferons maintained a considerable share owing to ongoing research into combination therapies, while the others segment is expected to grow significantly due to innovation in novel treatment modalities.

By age group, adults accounted for the largest share of 77.87% in 2026, attributed to higher transmission rates and expanded adult screening programs. The pediatric segment held a smaller share due to effective vaccination programs but is expected to grow moderately with expanding drug indications.

By route of administration, the oral segment dominated with a share of 94.76% in 2026, supported by convenience and patient compliance. Parenteral therapies are expected to grow steadily due to improved bioavailability and emerging injectable therapies.

By distribution channel, retail pharmacies led the market with a share of 52.53% in 2026, while online pharmacies are expected to grow at the highest CAGR due to increasing digital adoption.

Regional Outlook

North America dominated the market with a value of USD 1.32 billion in 2025, driven by high disease awareness and strong reimbursement policies. The U.S. market is projected to reach USD 1.36 billion by 2026.

Asia Pacific held the second-largest share and is expected to grow at the fastest rate due to high disease prevalence and availability of affordable generics, with China projected to reach USD 0.56 billion by 2026.

Europe maintained a substantial share, supported by advanced healthcare systems and rising HBV prevalence.

Latin America and the Middle East & Africa are expected to grow steadily due to increasing government-led elimination programs.

Competitive Landscape

The market is consolidated, with Gilead Sciences, Inc. and Bristol-Myers Squibb Company holding leading positions due to strong product portfolios and consistent sales. Other notable players include GSK plc, Arbutus Biopharma, Assembly Biosciences, Aligos Therapeutics, and Excision BioTherapeutics, focusing on pipeline expansion and innovative therapies.

Conclusion

The global hepatitis B therapeutics market is positioned for strong growth through the forecast period, driven by the rising global burden of hepatitis B, expanding screening programs, and continuous advancements in therapeutic innovation. With the market valued at USD 2.48 billion in 2025, projected to grow to USD 2.67 billion in 2026 and reach USD 6.66 billion by 2034, increasing adoption of novel antiviral combinations and curative treatment approaches is expected to reshape the treatment landscape. Despite challenges related to drug resistance and high treatment costs, sustained government initiatives and ongoing research and development efforts are anticipated to support long-term market expansion.

Segmentation By Drug Class

  • Nucleoside Analogues
  • Nucleotide Analogues
  • Interferons
  • Others

By Age Group

  • Adults
  • Pediatric

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Drug Class, Age Group, Route of Administration, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Hepatitis B, By Key Countries, 2025
  • 4.2. Key Industry Developments (Launches, Mergers, Acquisitions, Partnerships, etc.)
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Advancements in Hepatitis B Treatment
  • 4.5. Overview: Vaccination Coverage for Hepatitis B, Key Countries
  • 4.6. Impact of Tariffs on the Market

5. Global Hepatitis B Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Nucleoside Analogues
    • 5.1.2. Nucleotide Analogues
    • 5.1.3. Interferons
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Age Group
    • 5.2.1. Adolts
    • 5.2.2. Pediatric
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail Pharmacies
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Hepatitis B Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Nucleoside Analogues
    • 6.1.2. Nucleotide Analogues
    • 6.1.3. Interferons
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Age Group
    • 6.2.1. Adolts
    • 6.2.2. Pediatric
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Retail Pharmacies
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Hepatitis B Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Nucleoside Analogues
    • 7.1.2. Nucleotide Analogues
    • 7.1.3. Interferons
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Age Group
    • 7.2.1. Adolts
    • 7.2.2. Pediatric
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Hepatitis B Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Nucleoside Analogues
    • 8.1.2. Nucleotide Analogues
    • 8.1.3. Interferons
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Age Group
    • 8.2.1. Adolts
    • 8.2.2. Pediatric
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail Pharmacies
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Hepatitis B Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Nucleoside Analogues
    • 9.1.2. Nucleotide Analogues
    • 9.1.3. Interferons
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Age Group
    • 9.2.1. Adolts
    • 9.2.2. Pediatric
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Hepatitis B Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Nucleoside Analogues
    • 10.1.2. Nucleotide Analogues
    • 10.1.3. Interferons
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Age Group
    • 10.2.1. Adolts
    • 10.2.2. Pediatric
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Gilead Sciences, Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Bristol-Myers Squibb Company
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. GSK plc
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Excision BioTherapeutics, Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Arbutus Biopharma
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Assembly Biosciences, Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Aligos Therapeutics
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Barinthus Biotherapeutics
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 3: Global Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 4: Global Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 7: North America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 8: North America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 12: Europe Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 13: Europe Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 14: Europe Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 17: Asia Pacific Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 18: Asia Pacific Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 19: Asia Pacific Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 22: Latin America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 23: Latin America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 24: Latin America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Latin America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 27: Middle East & Africa Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 28: Middle East & Africa Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 29: Middle East & Africa Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Middle East & Africa Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Figure 1: Global Hepatitis B Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Hepatitis B Therapeutics Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Hepatitis B Therapeutics Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 4: Global Hepatitis B Therapeutics Market Value Share (%), by Route of Administration 2025 & 2034
  • Figure 5: Global Hepatitis B Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Hepatitis B Therapeutics Market Value Share (%), by Region, 2025 & 2034
  • Figure 7: North America Hepatitis B Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 8: North America Hepatitis B Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 9: North America Hepatitis B Therapeutics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 10: North America Hepatitis B Therapeutics Market Value Share (%), by Age Group, 2025
  • Figure 11: North America Hepatitis B Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 12: North America Hepatitis B Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 13: North America Hepatitis B Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Hepatitis B Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Hepatitis B Therapeutics Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Hepatitis B Therapeutics Market Value Share (%), By Country, 2025
  • Figure 17: Europe Hepatitis B Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 18: Europe Hepatitis B Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 19: Europe Hepatitis B Therapeutics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 20: Europe Hepatitis B Therapeutics Market Value Share (%), by Age Group, 2025
  • Figure 21: Europe Hepatitis B Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 22: Europe Hepatitis B Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 23: Europe Hepatitis B Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Hepatitis B Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Hepatitis B Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Hepatitis B Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Hepatitis B Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 28: Asia Pacific Hepatitis B Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 29: Asia Pacific Hepatitis B Therapeutics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 30: Asia Pacific Hepatitis B Therapeutics Market Value Share (%), by Age Group, 2025
  • Figure 31: Asia Pacific Hepatitis B Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 32: Asia Pacific Hepatitis B Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 33: Asia Pacific Hepatitis B Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Hepatitis B Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Hepatitis B Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Hepatitis B Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Hepatitis B Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 38: Latin America Hepatitis B Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 39: Latin America Hepatitis B Therapeutics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 40: Latin America Hepatitis B Therapeutics Market Value Share (%), by Age Group, 2025
  • Figure 41: Latin America Hepatitis B Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 42: Latin America Hepatitis B Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 43: Latin America Hepatitis B Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Hepatitis B Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Hepatitis B Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Hepatitis B Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Hepatitis B Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 48: Middle East & Africa Hepatitis B Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 49: Middle East & Africa Hepatitis B Therapeutics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 50: Middle East & Africa Hepatitis B Therapeutics Market Value Share (%), by Age Group, 2025
  • Figure 51: Middle East & Africa Hepatitis B Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 52: Middle East & Africa Hepatitis B Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 53: Middle East & Africa Hepatitis B Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Hepatitis B Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Hepatitis B Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Hepatitis B Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Hepatitis B Therapeutics Market Share (%), By Company, 2025